First Foundation Advisors Cuts Thermo Fisher Scientific Inc. Share Holdings (NYSE:TMO)

First Foundation Advisors reduced its stake in Thermo Fisher Scientific Inc. (NYSE:TMO – Free Report) by 10.4% during the second quarter, according to its most recent 13F filing with the SEC. The firm owned 733 shares of the medical research company’s stock after selling 85 shares during the period. First Foundation Advisors’ holdings in Thermo Fisher Scientific were worth $405,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. Signature Resources Capital Management LLC raised its stake in Thermo Fisher Scientific by 318.2% during the second quarter. Signature Resources Capital Management LLC now owns 46 shares of the medical research company’s stock worth $25,000 after purchasing an additional 35 shares in the last quarter. True Wealth Design LLC raised its stake in Thermo Fisher Scientific by 1,275.0% during the 4th quarter. True Wealth Design LLC now owns 55 shares of the medical research company’s stock worth $29,000 after purchasing another 51 shares in the last quarter. New Millennium Group LLC purchased a new position in Thermo Fisher Scientific during the second quarter valued at approximately $29,000. Stephens Consulting LLC boosted its stake in Thermo Fisher Scientific by 116.0% in the second quarter. Stephens Consulting LLC now owns 54 shares of the medical research company’s stock worth $30,000 after buying an additional 29 shares during the period. Finally, LifeSteps Financial Inc. purchased a new stake in shares of Thermo Fisher Scientific in the 1st quarter worth approximately $31,000. 89.23% of shares are currently held by institutional investors and hedge funds.

Analyst upgrades and downgrades

Several brokerages have recently weighed in on TMO. Stifel Nicolaus upped their target price on shares of Thermo Fisher Scientific from $600.00 to $615.00 and gave the stock a “buy” rating in a report on Thursday, July 25th. TD Cowen lifted their price target on Thermo Fisher Scientific from $648.00 to $658.00 and gave the company a “buy” rating in a report on Thursday, July 25th. Jefferies Financial Group restated a “buy” rating and set a $650.00 target price (up previously from $600.00) on shares of Thermo Fisher Scientific in a report on Monday, June 3rd. Royal Bank of Canada boosted their price objective on Thermo Fisher Scientific from $660.00 to $664.00 and gave the stock an “outperform” rating in a research report on Thursday, July 25th. Finally, Robert W. Baird boosted their target price on shares of Thermo Fisher Scientific from $620.00 to $632.00 and gave the company an “outperform” rating in a report on Thursday, July 25th . Four investment analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. The stock has a consensus rating of “Moderate Buy” and an average price target of $630.41, according to MarketBeat.com.

Read our latest TMO review

Insiders place their bets

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction dated Wednesday, July 31st. The shares were sold at an average price of $617.21, for a total value of $6,172,100.00. Following the transaction, the chief executive officer now directly owns 123,816 shares of the company’s stock, valued at approximately $76,420,473.36. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible via this link. In related news, VP Lisa P. Britt sold 3,624 shares of the company’s stock in a transaction on Friday, July 26th. The shares were sold at an average price of $613.02, for a total transaction of $2,221,584.48. Following the transaction, the vice president now owns 13,699 shares of the company’s stock, valued at $8,397,760.98. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Marc N. Casper sold 10,000 shares of the business’s stock in a transaction dated Wednesday, July 31st. The shares were sold at an average price of $617.21, for a total value of $6,172,100.00. Following the completion of the sale, the chief executive officer now directly owns 123,816 shares of the company’s stock, valued at approximately $76,420,473.36. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 23,084 shares of company stock valued at $14,094,292. 0.34% of shares are owned by company insiders.

Thermo Fisher Scientific Trading rose 1.5%

NYSE:TMO opened at $620.42 on Tuesday. The company has a quick ratio of 1.37, a current ratio of 1.72, and a debt-to-equity ratio of 0.64. Thermo Fisher Scientific Inc. it has a 52-week low of $415.60 and a 52-week high of $622.30. The stock’s 50-day moving average price is $585.64 and its 200-day moving average price is $578.80. The company has a market cap of $237.00 billion, a PE ratio of 39.80, a P/E/G ratio of 2.84 and a beta of 0.78.

Thermo Fisher Scientific (NYSE:TMO – Get Free Report ) last posted its quarterly earnings results on Wednesday, July 24th. The medical research company reported $5.37 EPS for the quarter, topping the consensus estimate of $5.13 by $0.24. Thermo Fisher Scientific had a net margin of 14.69% and a return on equity of 18.22%. The firm had revenue of $10.54 billion during the quarter, compared to the consensus estimate of $10.50 billion. In the same quarter last year, the firm earned $5.15 EPS. Thermo Fisher Scientific’s revenue for the quarter was down 1.4% year over year. On average, research analysts anticipate that Thermo Fisher Scientific Inc. will post 21.72 EPS for the current year.

Thermo Fisher Scientific Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, October 15th. Stockholders of record on Friday, September 13th will be paid a dividend of $0.39 per share. This represents an annualized dividend of $1.56 and a yield of 0.25%. The ex-dividend date is Friday, September 13. Thermo Fisher Scientific’s dividend payout ratio is currently 10.01%.

Thermo Fisher Scientific Company Profile

(Free Report)

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics and laboratory products and biopharmaceutical services in North America, Europe, Asia-Pacific and internationally. The company’s Life Sciences Solutions segment provides reagents, instruments and supplies for biological and medical research, drug and vaccine discovery and production, and infection and disease diagnosis; and solutions include biosciences, genetic sciences and biological manufacturing for the pharmaceutical, biotech, agricultural, clinical, healthcare, academic and government markets.

Featured stories

Get news and reviews for Thermo Fisher Scientific Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Thermo Fisher Scientific and related companies with MarketBeat.com’s FREE daily email newsletter.